Outcome based staging for clinically localized adenocarcinoma of the prostate

Journal of Urology

Volumn 158, Issue 4, 1997, Pages 1422-1426

  D'Amico, Anthony V ^a   Whittington, Richard ^a   Schultz, Delray ^a   Malkowicz, S Bruce ^a   Tomaszewski, John E ^a   Wein, Alan ^a  

^a NONE

Author keywords

Outcome assessment (health care); Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0030757744     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64230-7     Document Type: Article

References (24)

1. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., 152: 1732, 1994.
2. Culp, O. S.: Radical perineal prostatectomy: its past, present, and possible future. J. Urol., 98: 618, 1968.
3. Jewett, H. J., Eggleston, J. C. and Yawn, D. H.: Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. J. Urol., 107: 1034, 1972.
4. Benson, R. C., Jr., Tomera, K. M., Zincke, H., Fleming, T. R. and Utz, D. C.: Bilateral pelvic lympadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J. Urol., 131: 1103, 1984.
5. Blute, M. L., Nativ, O., Zincke, H., Farrow, G. M., Therneau, T. and Lieber, M. M.: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J. Urol., 142: 1262, 1989.
6. McNeal, J. E.: Origin and development of carcinoma in the prostate. Cancer, 23: 24, 1969.
7. Blackwell, K. L., Bostwick, D. G., Myers, R. P., Zincke, H. and Oesterling, J. E.: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J. Urol., 151: 1565, 1994.
8. McNeal, J. E.: Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum. Path., 23: 258, 1992.
9. McNeal, J. E., Bostwick, D. G., Kindrachuk, R. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Patterns of progression in prostate cancer. Lancet, 1: 60, 1986.
10. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Capsular penetration in prostate cancer. Significance for natural history and treatment. Amer. J. Surg. Path., 14: 240, 1990.
11. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990.
12. Stamey, T. A., McNeal, J. E., Freiha, F. S. and Redwine, E.: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol., 139: 1235, 1988.
13. Villers, A. A., McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J. Urol., 143: 1183, 1990.
14. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317: 909, 1987.
15. Noldus, J. and Stamey, T. A.: Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J. Urol., 155: 232, 1996.
16. D'Amico, A. V., Chang, H., Holoupka, E., Renshaw, A., Desjarden, A., Chen, M., Loughlin, K. and Richie, J.: Calculated prostate cancer volume: the optimal predictor of the actual prostate cancer volume. Urology, 49: 385, 1997.
17. Gleason, D. F.: Histologic grading and staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, pp. 171-187, 1977.
18. Myrtle, J. F., Klimley, P. G., Ivor, L. P. and Brun, J. F.: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. Adv. Cancer Diag. Hybritech Inc., 1986.
19. American Joint Committee on Cancer: Manual for Staging Cancer, 4th ed. Philadelphia: J. P. Lippincott Co., 1992.
20. Cox, D. R.: Regression models and life-tables. J. Roy. Stat. Soc. B., 34: 187, 1972.
21. Kaplan, E. L. and Meier, P.: Non-parametric estimation from incomplete observations. J. Amer. Stat. Assoc., 53: 457, 1958.
22. Lepor, H., Wang, B. and Shapiro, E.: Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology, 44: 199, 1994.
23. Marks, L. S., Treiger, B., Dorey, F. J., Fu, Y. S. and deKernion, J. B.: Morphometry of the prostate. I. Distribution of tissue components in hyperplastic glands. Urology, 44: 486, 1994.
24. Aihara, M., Lebovitz, R. M., Wheeler, T. M., Kinner, B. M., Ohori, M. and Scardino, P. T.: Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J. Urol., 151: 1558, 1994.